The overarching goal of the Mailloux lab is to create new T cell-based immunotherapies to treat cancer, and to make current cell therapies smarter, stronger, faster, and more readily available to all who may benefit. We focus on a suite of hypothesis-driven basic research projects that: 1) improve production methods and potency of effector lymphocyte products, 2) address challenges in the tumor microenvironment faced by adoptively transferred effector cells, and 3) develop and translate new immunotherapies.

To this end, we utilize a combination of conventional molecular and immunologic assays, as well as cutting edge technology and new approaches to study the immune response against the tumor. This includes in vitro cell culture-based approaches, in vivo animal models, and ex vivo work with primary human samples. A significant focus of our lab involves fluorescence-based approaches, such as high-parameter flow cytometry and multiplexed immunofluorescence.